Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
Neoantigen peptide vaccines have entered Phase II with a 67% response rate in melanoma combination therapy. While mRNA approaches grab headlines, peptide vaccines offer distinct advantages: simpler manufacturing, ambient-temperature stability, and a century of regulatory precedent.
The FDA approved 28 peptide drugs from 2020 to mid-2026, with the 2025 draft guidance establishing macrocycles as a distinct regulatory category. Manufacturing deficiencies account for 41% of peptide CRLs — the single largest source of regulatory failure.
Peptide API manufacturing costs range from $300 to $50,000+ per gram depending on length and complexity. HPLC purification accounts for 30-50% of total cost. This analysis breaks down the economics and reveals where experienced CDMOs focus their optimization efforts.
AI-designed peptides have entered clinical development with diffusion models achieving 34% experimental hit rates against undruggable targets. Machine learning is compressing peptide discovery timelines from 18 months to 6 weeks, but synthesizability and drug-likeness remain unsolved challenges.
Oral peptide delivery remains the holy grail of peptide therapeutics. With Rybelsus generating $4.2B in 2025 and $1.2B in new venture funding, technologies from SNAC to ionic liquids are progressively cracking the bioavailability barrier.
Peptide-drug conjugates combine tumor-homing peptides with cytotoxic payloads for targeted cancer therapy. With 23 clinical programs and 38% response rates in ADC-resistant patients, PDCs offer superior penetration and lower manufacturing costs than antibody-based alternatives.
Between 2027 and 2030, patents on 14 peptide drugs worth $32B will expire. The GLP-1 biosimilar opportunity is immense but capital-intensive. Smart innovators are already shifting to next-generation molecules — the patent cliff is a stress test, not a crisis.
GLP-1/GLP-2 co-agonists like dapiglutide are advancing through Phase II with improved tolerability profiles and complementary gut-barrier benefits. As the obesity market races toward $100B, multi-receptor agonism represents the next competitive frontier.
Antimicrobial peptides are moving beyond therapeutics into food preservation, crop protection, and aquaculture. With engineered nisin variants now commercial in Europe and AMP-expressing crops showing 73% disease reduction in field trials, the non-pharma peptide market is taking shape.
The global peptide therapeutics market crossed 8B in 2025, driven by GLP-1 agonists. With 212 candidates in clinical development and B+ in CDMO capacity expansion underway, peptides are transitioning from a single-class story to a multi-pillar growth narrative.
Continuous-flow solid-phase peptide synthesis is delivering 3.4× faster cycle times and 62% less solvent waste compared to batch methods. With the FDA's first flow-manufactured peptide approval in January 2026, the technology is crossing from academic promise to industrial reality.
Macrocyclic peptides are breaching the 85% of human proteins once considered undruggable. With 47 candidates in clinical development and AI-driven design achieving 34% hit rates, the modality is entering the therapeutic mainstream.
Matrixyl sends a fake distress signal to fibroblasts using a five-amino-acid collagen fragment called KTTKS. Here is the full molecular mechanism, clinical data, and what formulators get wrong about concentration and delivery.
Clean skincare brand Mad Hippie launches the Wrinkle Relaxing Eye Treatment ($34.99) — five peptide complexes including Syn-Ake, Argireline Amplified and Matrixyl Synthe'6 in a retinol- and Botox-free eye cream.
